|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/485 | (2006.01) |
| A61K 31/137 | (2006.01) | ||
| A61P 3/04 | (2006.01) |
| (11) | Number of the document | 3222280 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17156985.8 |
| Date of filing the European patent application | 2011-12-02 | |
| (97) | Date of publication of the European application | 2017-09-27 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-20 |
| (46) | Date of publication of the claims translation | 2021-05-10 |
| (30) | Number | Date | Country code |
| 419395 P | 2010-12-03 | US |
| (72) |
FLANAGAN, Shawn, US
DUNAYEVICH, Eduardo, US
|
| (73) |
Nalpropion Pharmaceuticals LLC,
10 North Park Place, Suite 201, Morristown, NJ 07960,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Vaistų biologinio prieinamumo padidinimas naltreksono terapijoje |
| INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY |
| Payment date | Validity (years) | Amount | |
| 2024-11-20 | 14 | 289.00 EUR |
| 2025-12-02 |